168267-01-4

Upstream product

• 168267-75-2 4-(5-trifluoromethyl-tetrazol-1-yl)-phenol 
• 23382-09-4 silicon dioxide hydrate 

Downstream Products

• 913092-72-5 2-(cyclopropylmethoxy)-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzaldehyde 
• 183808-94-8 2-ethoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzaldehyde 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-)

The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifuoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl- piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.

F-18 radiolabeled neurokinin-1 receptor antagonists

The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.